These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20103694)

  • 1. Effects of milnacipran on cardiac repolarization in healthy participants.
    Periclou A; Palmer RH; Zheng H; Lindamood C
    J Clin Pharmacol; 2010 Apr; 50(4):422-33. PubMed ID: 20103694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A thorough QT study of guanfacine.
    Martin P; Satin L; Kahn RS; Robinson A; Corcoran M; Purkayastha J; Youcha S; Ermer JC
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):301-16. PubMed ID: 25109412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
    Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis.
    Tyl B; Kabbaj M; Azzam S; Sologuren A; Valiente R; Reinbolt E; Roupe K; Blanco N; Wheeler W
    J Clin Pharmacol; 2012 Jun; 52(6):893-903. PubMed ID: 21642470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects.
    Huennemeyer A; Nassr N; Bredenbröker D; Lahu G
    Expert Opin Drug Saf; 2011 Jul; 10(4):509-19. PubMed ID: 21585288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
    Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
    Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects.
    Ayalasomayajula S; Yeh CM; Vaidyanathan S; Flannery B; Dieterich HA; Howard D; Bedigian MP; Dole WP
    J Clin Pharmacol; 2008 Jul; 48(7):799-811. PubMed ID: 18490495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
    Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
    Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
    Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
    Gottfridsson C; Carlson G; Lappalainen J; Sostek M
    Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
    Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
    Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
    Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.
    Charbit B; Alvarez JC; Dasque E; Abe E; Démolis JL; Funck-Brentano C
    Anesthesiology; 2008 Aug; 109(2):206-12. PubMed ID: 18648229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
    Luo WL; Crumley T; Ebel D; Atiee GJ; Royalty J; Johnson-Levonas AO; Wagner J; Lai E
    J Clin Pharmacol; 2010 Nov; 50(11):1273-9. PubMed ID: 20107202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.